TIDMHCM
Hutchison China Meditech Limited
21 March 2017
Press Release
Chi-Med to host R&D Briefings on March 29 & 30, 2017
London: Tuesday, March 21, 2017: Hutchison China MediTech
Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that it will
host Research & Development ("R&D") briefings in London and
New York to provide an overview of the Company's clinical pipeline
of eight novel drug candidates. The events for analysts and
investors will take place in London on Wednesday, March 29, and in
New York on Thursday, March 30, 2017.
Chi-Med is a China-based biopharmaceutical company focused on
discovering and developing targeted therapies for oncology and
immunological diseases for the global market. The Company has 30
ongoing clinical trials with eight novel drug candidates, which are
expected to report a steady flow of pivotal Phase III trial results
from this year onwards. Chi-Med's first drug is targeted to launch
next year in China.
The Chi-Med management team will outline the Company's R&D
strategy and discuss its drug candidate pipeline during the
briefings.
Date: Wednesday, March Thursday, March 30,
29, 2017 2017
========== ============================= ========================
City: London New York
========== ============================= ========================
Time: 9:15am Registration 8:00am Registration
9:30am-12:30pm Program & Breakfast
Presentation 8:30am-11:30am Program
Lunch will be provided Presentation
afterwards
Address: South Place Hotel, W Hotel, 541 Lexington
3 South Place, London, Ave, New York, NY
EC2M 2AF 10022
========== ============================= ========================
Keynote Dr Susan Galbraith,
Speaker: Vice President, AstraZeneca
PLC ("AstraZeneca")
========== ============================= ========================
The briefing on Wednesday, March 29, 2017 in London will begin
with a keynote presentation from Dr Susan Galbraith, Vice President
of Oncology Innovative Medicines and Early Development at
AstraZeneca.
Mr Christian Hogg, Chief Executive Officer; Dr Weiguo Su,
Executive Vice President and Chief Scientific Officer; Dr Zhenping
Wu, Senior Vice President of Pharmaceutical Sciences; and Dr May
Wang, Senior Vice President of Business Development & Strategic
Alliances, will be presenting on Chi-Med's research &
development and partnering activities. Chi-Med currently has
partnerships with AstraZeneca, Eli Lilly and Company and Nestlé
Health Science S.A.
To register for the London briefing, please contact Dr Marine
Perrier by telephone at +44 20 7282 1068 or by email at
marine.perrier@citigatedr.co.uk.
To register for the New York briefing, please contact Matt Beck
by telephone at +1 646 378 2933 or by email at
mbeck@troutgroup.com.
No new material trading or financial information will be
disseminated at the meeting. Following the meeting, the
presentations will be made available at
http://www.chi-med.com/news/.
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which
researches, develops, manufactures and sells pharmaceuticals and
healthcare products. Its Innovation Platform, Hutchison MediPharma
Limited, focuses on discovering and developing innovative
therapeutics in oncology and autoimmune diseases for the global
market. Its Commercial Platform manufactures, markets, and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 0001). For more information,
please visit: www.chi-med.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements reflect Chi-Med's current expectations regarding future
events, including its expectations for the clinical development of
savolitinib, fruquintinib, sulfatinib, epitinib, theliatinib,
HMPL-523, HMPL-689, HMPL-453 and other drug research and
development projects, including plans for clinical studies, its
expectations as to whether such studies would meet their primary or
secondary endpoints, and its expectations as to the timing of the
completion and the release of results from such studies.
Forward-looking statements involve risks and uncertainties. Such
risks and uncertainties include, among other things, assumptions
regarding enrollment rates, timing and availability of subjects
meeting a study's inclusion and exclusion criteria, changes to
clinical protocols or regulatory requirements, unexpected adverse
events or safety issues, the ability of drug candidate sulfatinib
to meet the primary or secondary endpoint of a study, to obtain
regulatory approval in different jurisdictions, to gain commercial
acceptance after obtaining regulatory approval, the potential
market of sulfatinib for a targeted indication and the sufficiency
of funding. Existing and prospective investors are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof. For further discussion of these
and other risks, see Chi-Med's filings with the U.S. Securities and
Exchange Commission and on AIM. Chi-Med undertakes no obligation to
update or revise the information contained in this press release,
whether as a result of new information, future events or
circumstances or otherwise.
CONTACTS
Investor Enquiries
Christian Hogg, CEO +852 2121 8200
UK and International Media Enquiries
Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk
US Based Media Enquiries
Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com
Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com
Investor Relations
Matt Beck, The Trout Group +1 (917) 415 1750 (Mobile) mbeck@troutgroup.com
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile) david.dible@citigatedr.co.uk
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEANDFASXXEEF
(END) Dow Jones Newswires
March 21, 2017 06:08 ET (10:08 GMT)
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From Apr 2023 to Apr 2024